CagriSema (Cagrilintide + Semaglutide) Combination Therapy: Clinical Evidence from the REDEFINE Trial Program

Overview

CagriSema is an investigational combination therapy developed by Novo Nordisk that co-administers cagrilintide, a long-acting amylin/calcitonin receptor agonist, with semaglutide, a GLP-1 receptor agonist. The rationale rests on complementary mechanisms: semaglutide reduces appetite and gastric emptying via GLP-1 receptor activation, while cagrilintide suppresses glucagon secretion and promotes satiety through amylin receptor pathways.

Clinical Evidence

The REDEFINE Phase 2 trial demonstrated that the combination of cagrilintide and semaglutide achieved substantially greater weight reduction than either agent alone or placebo. Reported mean weight loss approached approximately 22–23% at the highest dose combination, representing one of the most pronounced pharmacological weight-loss effects reported in a clinical trial setting to date.

The REDEFINE Phase 3 program comprises multiple trials (REDEFINE 1 through 5) enrolling thousands of participants across diverse populations, with endpoints including sustained weight loss, metabolic improvement, and cardiovascular outcomes. Results from these registrational trials will determine regulatory submission for obesity and potentially type 2 diabetes indications.

Mechanistic Rationale

The dual-agonist approach leverages non-overlapping satiety pathways. Amylin (islet amyloid polypeptide) is co-secreted with insulin from pancreatic beta cells and acts centrally to reduce food intake, slow gastric emptying, and decrease postprandial glucagon. GLP-1 receptor agonism similarly reduces appetite but through distinct central and peripheral pathways. The combination is hypothesized to produce additive or synergistic weight loss without proportionally increasing adverse events.

Safety Considerations

The most frequently reported adverse events are gastrointestinal in nature (nausea, vomiting, diarrhea), consistent with the known tolerability profiles of both drug classes. Hypoglycemia risk is low in non-diabetic populations. Long-term cardiovascular and thyroid safety data are being collected in the Phase 3 program.

Evidence Assessment

This compound is supported by active, large-scale Phase 2 and Phase 3 clinical trials in human subjects. It represents a high-evidence-tier intervention within the weight management category.